RD238 - Opioid Overdose Risk Mitigation - August 31, 2015


Executive Summary:
Report on the risk mitigation guidelines on the prescription of the class of potent pain medicines known as extended-release and long-acting (ER/LA) opioid analgesics to include co-prescription of an opioid antagonist, approved by the U.S. Food and Drug Administration (FDA), for administration by family members or careg